Pajjiż: Irlanda
Lingwa: Ingliż
Sors: HPRA (Health Products Regulatory Authority)
ROPINIROLE HYDROCHLORIDE
Accord Healthcare Limited
1 Milligram
Film Coated Tablet
2012-02-24
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ropinirole 1 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 1 mg Ropinirole (as hydrochloride). Excipient (s): Each 1 mg film-coated tablet contains 47.86 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Round biconvex, plain on both sides, green. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of Parkinson’s disease under the following conditions: Initial treatment as monotherapy, in order to delay the introduction of levodopa. In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations). Symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral use. PARKINSON’S DISEASE Adults Individual dose titration against efficacy and tolerability is recommended. Ropinirole tablets should be taken three times a day, preferably with meals to improve gastrointestinal tolerance. _Treatment initiation_ The initial dose of ropinirole should be 0.25 mg three times daily for 1 week. Thereafter, the dose of ropinirole can be increased in 0.25 mg three times daily increments, according to the following regimen: _Therapeutic regimen_ After the initial titration, weekly increments of 0.5 to 1 mg three times daily (1.5 to 3 mg/day) of ropinirole may be given. Week 1 2 3 4 Unit dose (mg) of ropinirole 0.25 0.5 0.75 1.0 Total daily dose (mg) of ropinirole 0.75 1.5 2.25 3.0 IRISH MEDICINES BOARD ____________________________________________________________________________________________________ Aqra d-dokument sħiħ